Given a box of medicine brought back from abroad, do not reach for the dictionary first. Turn to the "Drug name" section of the insert and you will often find several lines side by side: the generic name, the brand name, the chemical name, the English name, sometimes a romanised form and an alias. They refer to the same box, but their status is entirely different. A translator's first job is not to translate; it is to work out which of them may be changed and which can only be copied.
The work resembles identifying a person: a job title on a business card can be translated, while the name on an identity document should not be casually altered. This matters even more with medicines, because one wrong word can make a reader think a different drug is being discussed. The origins of these names are all available in public sources, which makes them a useful lesson.

Three names, three kinds of status
A chemical name comes from molecular structure, assembled by bodies such as the International Union of Pure and Applied Chemistry under systematic rules. It is precise and unique, and almost impossible to remember. A popular science column in Beijing Daily gives an example: 2,3,4,5,6-pentahydroxy-2-hexenoic acid-4-lactone is simply vitamin C, while another name that reads like a tongue twister turns out to be atorvastatin calcium, a lipid-lowering drug. Such names belong mainly to professional documents; in an insert for patients they usually sit in a corner.
The generic name is the legal one. The World Health Organization has promoted International Nonproprietary Names since 1950, and by the time cited in the science articles it had named roughly 8,500 pharmaceutical substances. China's approved drug names (CADN) are set by the Chinese Pharmacopoeia Commission under its naming principles, with English names following INN wherever possible and a strict "one drug, one name" rule. A brand name is a registered, trademark-protected product name belonging to a manufacturer; the same ingredient can carry a different one with every maker. It is normally copied rather than translated, and must never be treated as a generic name.
One more line on the insert is often overlooked: the romanised form. It is neither an English name nor a brand name; it exists to show pronunciation in a Chinese context, and a translator normally copies it rather than inventing a new spelling. Compound preparations are harder still: a long string of ingredients has to be sorted into generic names and excipients before a word is written. Recognising all the fields at once saves more time than guessing sentence by sentence.
A stem is a medicine's family name
Drug names are hard to memorise, but systematic stems do much of the work. Drugs in the same class with similar pharmacological action are given a shared stem: penicillins use -cillin in English and "xilin" in Chinese; antivirals use -vir and "wei". Seeing the stem tells you roughly which family a medicine belongs to. The Chinese Pharmacopoeia Commission's principles also ask translators to keep established stem renderings so that related drugs show their systematic relationship.
For a translator this is both a hint and a constraint. With an unfamiliar new name, checking the stem saves half the detour; when writing, restraint is needed, because a smoother new transliteration would break that system. A terminology table benefits from a separate stem column, with Chinese and English equivalents and a few examples, so that a new member of the same family can simply be added underneath. Much of what is called experience is knowing where improvisation is not allowed.
Stems are also a way to verify. When a drug name in a document looks doubtful, check whether it carries a familiar stem, then go back to the official name; that removes half the temptation to trust second-hand sources. Among the public references, the Chinese Pharmacopoeia Commission's naming principles and its stem renderings are the most direct, while the World Health Organization's INN documents give the English side. Popular science is fine for an introduction, but the official material should govern the final wording.
Why a clever old Chinese name stepped aside
The example most often quoted is paracetamol. Its former Chinese name, "Pu Re Xi Tong", was a neat piece of work: one half suggested bringing down a fever, the other suggested stopping pain, and the sound was close to the original word. It is a fine case of combining sound and meaning. Unfortunately the naming principles explicitly discourage names that hint at pharmacological, physiological or therapeutic effects. The official Chinese generic name became "Dui Yi Xian An Ji Fen", a plain descriptive rendering of the chemical structure, and the more colloquial old name was retired to the status of former name.
Changes like this are where translation goes wrong most easily. An older patient says the former name, the box prints the official generic name, and an overseas insert says paracetamol, so three wordings appear in one set of papers. The safe approach is not to pick one "correct" answer and delete the others, but to lead with the legal generic name, label the alias as a former name and keep the original wording, so that anyone checking later can follow the trail. The sources are the naming principles published by the Chinese Pharmacopoeia Commission and the World Health Organization's guidance on the use of INNs, along with its short public explainer.
What to do first with a box of medicine
The order is fixed. Find the legal generic name in the "Drug name" section, then check whether the foreign version uses the INN or a brand. Copy the chemical name, aliases, dosage form and strength into separate rows of the terminology table, record the brand name verbatim and mark it as not to be changed. Keep dosage units and dates exactly as written, and if a conversion is needed say so separately rather than quietly changing the text. Finally read through to confirm that the same medicine carries the same name on every page. The WHO INN guidance and its short essay "What's in a name?" are both worth keeping close at hand.
The routine is plain, but it prevents most rework. Drug names are not literature: the standard is not elegance but whether a reader can tell at a glance that this is the same thing. With the new reimbursement list published, names and information fields are due for another round of updates, and our industry note covers the document-level consequences; the comparison table revised again and again in the company note shows the same routine in an office. Next time three names sit side by side on a box, you will probably look for the stem first.
